Signify Premium Insight: Ultromics’ AI Heart Breakthrough

Ultrasound AI vendor Ultromics has recently been granted Breakthrough Device Status for its artificial intelligence platform for cardiac amyloidosis detection.

The platform, named EchoGo Amyloidosis, uses AI to analyse echocardiograms in order to detect the presence of cardiac amyloidosis, using only a single ultrasound view of the heart. Ultromics says the tool will facilitate the earlier diagnosis of amyloidosis patients, with the condition otherwise going unnoticed until the disease has advanced, delaying treatment and adversely affecting patient outcomes.

In granting Breakthrough Device Designation, the FDA has recognised the solution’s potential for providing more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. This is very relevant in the case of amyloidosis patients which, according to Ultromics, suffer a five-year mortality rate of 44%-55% after diagnosis, if the condition is not caught early enough.